Related Experiment Videos
A controlled trial of idebenone in Huntington's disease
N G Ranen1, C E Peyser, J T Coyle
1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Insights
Idebenone did not significantly slow Huntington's disease progression in this 1-year trial. Larger, multicenter studies are needed to detect potential therapeutic effects in Huntington's disease (HD) patients.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Oxidative stress and impaired mitochondrial metabolism are implicated in HD pathogenesis.
- Idebenone, an antioxidant, has been investigated as a potential therapeutic agent.
Purpose of the Study:
- To evaluate the efficacy of idebenone in slowing the progression of Huntington's disease (HD).
- To assess the impact of idebenone on functional status and neurological examination in HD patients.
Main Methods:
- A 1-year, double-blind, randomized, placebo-controlled study.
- One hundred patients with clinically diagnosed Huntington's disease (HD) were enrolled.
- Participants received either idebenone or a placebo.
Main Results:
- Ninety-one patients completed the study.
- No significant differences were observed between the idebenone and placebo groups on the Huntington's Disease Activities of Daily Living Scale (ADL) or the Quantified Neurologic Examination (QNE).
- Sample size calculations indicated that a larger study is required to detect smaller treatment effects.
Conclusions:
- Idebenone did not demonstrate significant efficacy in slowing Huntington's disease (HD) progression in this study.
- Future therapeutic trials for HD necessitate larger sample sizes and multicenter collaboration to achieve adequate statistical power.
Abstract:
One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.